KA Insider Trading

Insider Ownership Percentage: 23.70%
Insider Buying (Last 12 Months): $100,196.00
Insider Selling (Last 12 Months): $0.00

Kineta Insider Trading History Chart

This chart shows the insider buying and selling history at Kineta by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Kineta Share Price & Price History

Current Price: $0.45
Price Change: Price Decrease of -0.02 (-4.25%)
As of 05/23/2024 01:00 AM ET

This chart shows the closing price history over time for KA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Kineta Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/6/2023Raymond J BartoszekDirectorBuy250$4.50$1,125.0017,206View SEC Filing Icon  
12/4/2023Raymond J BartoszekDirectorBuy1,000$4.33$4,330.0015,956View SEC Filing Icon  
11/28/2023Craig W PhilipsPresidentBuy3,000$3.27$9,810.0060,811View SEC Filing Icon  
11/28/2023Shawn IadonatoCEOBuy900$3.33$2,997.00671,130View SEC Filing Icon  
9/20/2023Craig W PhilipsPresidentBuy600$2.54$1,524.0054,911View SEC Filing Icon  
9/20/2023Pauline KennyGeneral CounselBuy1,500$2.58$3,870.0018,448View SEC Filing Icon  
9/20/2023Shawn IadonatoCEOBuy10,000$2.50$25,000.00670,230View SEC Filing Icon  
9/18/2023Keith BakerCFOBuy5,000$2.13$10,650.0016,880View SEC Filing Icon  
9/18/2023Raymond J BartoszekDirectorBuy2,500$2.08$5,200.0012,956View SEC Filing Icon  
9/15/2023Raymond J BartoszekDirectorBuy500$2.18$1,090.0010,456View SEC Filing Icon  
9/14/2023Thierry GuillaudeuxInsiderBuy10,000$2.00$20,000.0021,696View SEC Filing Icon  
6/16/2023Keith BakerCFOBuy5,000$2.92$14,600.0011,880View SEC Filing Icon  
3/20/2023Craig W PhilipsPresidentSell872$3.29$2,868.8866,977View SEC Filing Icon  
3/20/2023Pauline KennyGeneral CounselSell544$3.29$1,789.7617,806View SEC Filing Icon  
3/20/2023Shawn IadonatoCEOSell1,119$3.29$3,681.51666,287View SEC Filing Icon  
3/17/2023Craig W PhilipsPresidentSell1,231$4.94$6,081.1467,849View SEC Filing Icon  
3/17/2023Pauline KennyGeneral CounselSell767$4.94$3,788.9818,350View SEC Filing Icon  
3/17/2023Shawn IadonatoCEOSell1,580$4.94$7,805.20667,406View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Kineta (NASDAQ:KA)

30.32% of Kineta stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at KA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Kineta Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/13/2024Armistice Capital LLC825,792$3M0.0%-11.2%7.948%Search for SEC Filing on Google Icon
11/15/2023Armistice Capital LLC930,000$3.16M0.0%+6.2%8.951%Search for SEC Filing on Google Icon
11/9/2023Manchester Capital Management LLC10,216$35K0.0%N/A0.098%Search for SEC Filing on Google Icon
2/13/2023Artal Group S.A.31,055$0.20M0.0%N/A2.004%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Kineta logo
Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.
Read More on Kineta

Today's Range

Now: $0.45
Low: $0.44
High: $0.47

50 Day Range

MA: $0.53
Low: $0.34
High: $0.67

52 Week Range

Now: $0.45
Low: $0.33
High: $5.39

Volume

30,193 shs

Average Volume

255,748 shs

Market Capitalization

$5.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.49

Who are the company insiders with the largest holdings of Kineta?

Kineta's top insider investors include:
  1. Shawn Iadonato (CEO)
  2. Craig W Philips (President)
  3. Thierry Guillaudeux (Insider)
  4. Pauline Kenny (General Counsel)
  5. Raymond J Bartoszek (Director)
  6. Keith Baker (CFO)
Learn More about top insider investors at Kineta.